SEATTLE (PRWEB) November 09, 2017
Ace Laboratories, Inc. (http://www.acelabsseattle.com) announced today that the United States Patent and Trademark Office has issued patent number 9,808,430 directed to compositions and methods relating to resveratrol, the active ingredient in the Company’s resveratrol lozenges.
The United States Patent and Trademark Office (USPTO) had previously issued U.S. patent number 9,125,858 in September 2015, also relating to resveratrol compositions and methods.
“We are pleased to report that Ace’s licensed technology received expanded patent protection from the USPTO,” said Chip Jacob, Chief Executive Officer of Ace Laboratories, Inc. “This is another important milestone in building the company’s intellectual property portfolio.”
About Ace Laboratories, Inc.
Ace Laboratories is focused on enhancing human health via the application of its proprietary technology to unlock the therapeutic potential of resveratrol. The company’s lead pharmaceutical product candidate, AIC-101, is a pharmaceutical formulation of resveratrol delivered in a lozenge. Ace plans to investigate AIC-101 in vascular and inflammatory indications such as Alzheimer’s disease and Mild to Moderate Traumatic Brain Injury/Concussion.
AIC-101 is a pharmaceutical formulation of resveratrol, a natural polyphenol found in red wine. The resveratrol molecule captured public interest in 2006 after a landmark study showed that it improved the health-span of rodents. In the decades since, a number of human clinical trials have demonstrated that resveratrol has potential to be helpful to patients with vascular and Alzheimer’s diseases, and other conditions associated with aging. However, the molecule’s large-scale potential has been constrained to date by poor oral bioavailability and dose-limiting gastrointestinal side effects. The Company’s management believes that its proprietary technology may effectively address these limitations. Further information about Ace Laboratories, Inc. can be found at: http://www.acelabsseattle.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Ace Laboratories’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with funding, product commercialization and commercial operations, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Ace Laboratories, Inc.